SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs Phase 3 REGAL topline results for GPS, with managements stated November timeline intensifying focus on the final analysis. Traders are split between optimistic expectations and short-squeeze speculation versus concerns about the binary outcome, delays, and recent share-price weakness.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention after quarterly results and an upbeat revenue outlook, with traders highlighting cloud growth and a reported Microsoft deal. Bulls emphasize the raised guidance and AI demand, while skeptics point to widening losses, heavy spending, and whether growth justifies the valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing was pushed to mid-2027 amid FDA dialogue and assay-refinement work, prompting a sharp selloff and concern about a longer catalyst gap. Traders are split between viewing it as a manageable manufacturing/CMC delay with clinical data intact and questioning managements credibility and the risk of further delays or dilution.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos quarterly results beat expectations and the company raised its outlook, including its AI infrastructure ambitions. Traders are divided over the muted, volatile reaction: some see profit-taking despite strong results, while others question whether AI demand will translate into durable growth.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A disappointing third-quarter report, softer sequential ANKTIVA sales, and concerns about cash burn, possible dilution, and limited management guidance are driving the selloff discussion. Some traders view the reaction as excessive and point to the positive BCG-nave trial result and potential expansion, while others question commercial execution and the funding outlook.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Hot inflation data has lifted Treasury yields and Fed rate-hike expectations, while a stronger dollar has pressured gold and driven a sharp GLD selloff. Traders are split between buying the dip and expecting further declines, with some questioning golds safe-haven appeal amid the weakness.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is drawing attention after its Q3 earnings report, with traders weighing strong revenue and profit growth and improving efficiency against concerns about rising delinquencies, credit quality, and whether the results met expectations. Reactions are split, with some viewing the selloff despite solid results as an overreaction and others seeing weaker credit metrics and muted stock performance as reasons for caution.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials quarterly results topped expectations and its next-quarter outlook was stronger than consensus, but the shares barely responded and sold off. Traders are debating whether the good news was already priced in, with some questioning how strong the guidance looks after adjusting for an extra week in the quarter; others point to options volatility and broader weakness in chip stocks.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

A sharp selloff followed Cardinals weak quarterly results, withdrawn full-year guidance and disclosure that its CFO plans to leave, with traders focused on worsening project margins and managements execution. The community is split between concerns about further deterioration and bankruptcy risk, and hopes that the stock is oversold and the authorized buyback could support a recovery; the authorization does not confirm that repurchases have begun.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Anthropics Claude Sheets and other workplace tools are fueling concern that competition could pressure Microsoft 365 and Copilot, with traders linking the launch to weakness in MSFT shares. The debate is whether new AI tools can displace deeply embedded enterprise software or pose only a limited threat to Microsofts established workflows.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of +15.00% and -5.52%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of +8.33% and +31.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CAMP Expands Its Team as the Race to Unlock Next-Generation RNA Therapeutics Accelerates

Talent is often one of the earliest indicators of a biotechnology company's long-term ambitions. That theme was reinforced this week as CAMP4 Therapeutics (NASDAQ:CAMP) announced an inducement equity award to a newly hired employee under Nasdaq Listing Rule 5635(c)(4), a standard mechanism that allows listed companies to use equity grants as a recruiting incentive for new hires. While modest in size, an option to purchase 8,000 shares, the announcement signals continued investment in building the team behind CAMP4's clinical-stage pipeline.

New Strong Sell Stocks for July 16th

AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Expands By 13.1%

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 468,369...

CAMP4 Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a class of RNA-targeting therapeutics for upregulating gene expression and restoration of healthy protein levels to treat a broad range of genetic diseases. Its lead product candidate is CMP-002. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Bullish Sentiment

Nvidia ($NVDA) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Stocktwits

) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Stocktwits Polls

Calamp Corp.

$CAMP 🚀🔥 VERY BULLISH! $124.5M in cash, runway through 2028, ASCEND Phase 1/2 trial officially underway, first patient dosing expected by year-end, and SHANK3 advancing in 2027! Revenue up 139% YoY! 💰📈 The company is funded, executing, and moving closer to major clinical catalysts. The market is sleeping on this one! 🧬💎

Feed

News

Sentiment

Earnings

Fundamentals

Info

CAMP Calamp Corp.

Fundamentals

Latest CAMP News